Y400

Y400 is an investigational drug currently being studied for the treatment of neovascular age-related macular degeneration (nAMD). It is administered via intravitreal injection. Early clinical data suggest that Y400 may help normalize gut flora and improve liver function, though its primary focus in ongoing trials is ophthalmic—specifically targeting nAMD. The exact mechanism of action has not been disclosed in public sources as of June 2025. A multicenter, dose-escalating Phase 1/2 clinical trial is underway to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and efficacy compared to aflibercept in patients with nAMD[1].